The U.S. Drug Enforcement Administration (DEA) has provided clarification regarding a specific question on its Medical Marijuana Dispensary Information Submission form, which is part of the broader DEA Schedule III registration process for medical cannabis businesses. The question, which asks applicants to disclose prior involvement in controlled substance activities without DEA authorization, had raised concerns among industry operators.
Following U.S. Acting Attorney General Todd Blanche’s announcement on April 23, 2026, to reschedule FDA-approved cannabis products and state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA), state-licensed medical cannabis businesses are now required to register their operations with the DEA. This compliance is expected to provide Section 280E tax relief, a significant financial consideration for many operators.
The DEA Diversion Control Division opened its registration portal for dispensaries on April 29, 2026. Companies including Trulieve, Verano, and Green Thumb Industries reportedly submitted their applications promptly. A separate portal for state-licensed medical cannabis cultivators, manufacturers, testing laboratories, and distributors is anticipated to open in the coming weeks, as reported by Cannabis Business Times on May 11, 2026.
A particular point of contention for many applicants emerged in Section 4 of the DEA’s Medical Marijuana Dispensary Information Submission form, under the header “Liability Questions.” The question asks: “Has anyone who will be involved in the ownership or operation of the firm previously manufactured, distributed, and/or dispensed any controlled substance without a DEA registration authorizing such activity?”
For most state-licensed medical cannabis dispensaries, operating under state law has historically meant engaging in activities that, while legal at the state level, were not authorized by federal DEA registration. Consequently, answering “yes” to this question would effectively acknowledge prior federal non-compliance, leading to apprehension among operators.
In response to inquiries from Cannabis Business Times on April 29, 2026, the DEA Media Affairs team responded to CBT’s inquiry via email, clarifying the intent behind the question. The DEA stated that the question “should be understood as part of a standard information-gathering process being applied in a changing regulatory landscape. It is not intended to serve as a categorical barrier, but rather to support a complete and fair evaluation of each application.”
The agency further elaborated:
The DEA emphasized that the application is the initial step in a broader process that includes pre-registration inspections and direct engagement with applicants. These steps aim to facilitate compliance with federal law while ensuring public health and safety, providing administrative processes for applicants to address any arising issues.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
Based in Australia, we publish industrial hemp and cannabis news, research and industry reports from around the world. Learn more about Hemp Gazette.
© Hemp Gazette